Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAi

PUBLISHER: Grand View Research | PRODUCT CODE: 1300999

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1300999

mRNA Therapeutics Contract Development & Manufacturing Market Size, Share & Trends Analysis Report By Application (Viral Vaccines, Protein Replacement Therapies), By Indication, By End-use, By Region, And Segment Forecasts, 2023 - 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

mRNA Therapeutics Contract Development & Manufacturing Market Growth & Trends

The global mRNA therapeutics contract development and manufacturing market is expected to reach USD 8.35 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 10.5% from 2023 to 2030. Advances in mRNA technologies and cellular delivery systems coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways have limitless potential that could revolutionize medicine, representing lucrative growth opportunities for the mRNA therapeutics contract development and manufacturing (CDMO) market.

Increasing investments in R&D for the development of mRNA therapeutics and a strong product pipeline are also propelling the growth of the market. For instance, according to the U.S. National Library of Medicine database, as of summer 2021, over 1,800 clinical studies involving mRNA were listed in the U.S. Approximately one-quarter of which were in phase II. Nearly 60% of candidates target solid tumors, while 30% of candidates are vaccines. The remaining ones are used to treat conditions like autoimmune disorders, colorectal cancer, and Lyme disease. Additionally, mRNA is being researched as a possible nonviral gene therapy delivery method.

In addition, the development of novel therapeutics to address unmet medical needs is altering the market for products. The need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats, is being driven by the rise in molecular complexity. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

With the introduction and widespread usage of mRNA vaccinations to stop the COVID-19 pandemic in 2020, mRNA technology platforms had a breakthrough. At the end of 2019, the combined market capitalization of the five publicly listed firms that specialize in mRNA platforms was USD 5 billion, according to a research paper released in October 2021. That capitalization exceeded USD 300 billion as of August 2021. Consequently, indicating that the COVID-19 outbreak has increased the demand for mRNA.

mRNA Therapeutics Contract Development & Manufacturing Market Report Highlights

  • The infectious diseases segment dominated the market and accounted for the entire revenue share of 100% in 2022, due to the launch of various COVID-19 vaccines that primarily used mRNA
  • The metabolic and genetic diseases segment is anticipated to undergo maximum growth with a CAGR of 11.65%, due to the presence of a strong pipeline under research for cancer therapeutics
  • Viral vaccines segment dominated the market in 2022 and contributed towards the entire revenue share of 100% owing to the availability and launch of various vaccines for the treatment of viral infection (COVID-19)
  • Cancer immunotherapies is expected to experience maximum growth over the forecast period due to increased focus to develop products for the treatment of cancer and favorable results presented by mRNA for the same in clinical trials
  • Biotech companies held the highest market share of 62.56% in 2022 due to vigorous efforts by these companies to launch COVID-19 vaccines to control the pandemic
  • The Government & Academic Research Institutes segment is anticipated to witness the fastest CAGR of 10.81% over the forecast owing to the rise in the number of clinical research supporting the demand for mRNA
  • In Asia Pacific, the market is expected to register the fastest growth rate of 9.1% CAGR over the forecast period. Due to the extremely rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future
Show more
Product Code: GVR-4-68040-083-7

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Data Visualization
    • 1.5.1. Commodity Flow Analysis
      • 1.5.1.1. Approach 1 Commodity flow approach
      • 1.5.1.2. Approach 2 Country wise market estimation using bottom up approach
  • 1.6. Data Validation & Publishing
  • 1.7. Global Market CAGR Calculation
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segmental Snapshot
  • 2.3. Competitive Insights Snapshot

Chapter 3. Market Variables, Trends, and Scope

  • 3.1. Market Lineage
    • 3.1.1. Parent Market Analysis
    • 3.1.2. Ancillary Market Analysis
  • 3.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market - Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. High adoption of mRNA in vaccines
      • 3.2.1.2. High number of researches in mRNA therapeutics
      • 3.2.1.3. Fundings for mRNA researches
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of research
      • 3.2.2.2. Availability of substitute therapy at low cost.
  • 3.3. Business Environmental Tools Analysis mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis
  • 3.4. COVID-19 Impact Analysis

Chapter 4. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Application Estimates & Trend Analysis

  • 4.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By Application Key Takeaways
  • 4.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Application Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Viral Vaccines
    • 4.3.1. Viral Vaccines Development Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 4.4. Protein Replacement Therapies
    • 4.4.1. Protein Replacement Therapies Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 4.5. Cancer Immunotherapies
    • 4.5.1. Cancer Immunotherapies Market Estimates And Forecasts, 2020 - 2030 (USD Million)

Chapter 5. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Indication Estimates & Trend Analysis

  • 5.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By Indication Key Takeaways
  • 5.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Indication Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Infectious Diseases
    • 5.3.1. Infectious Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 5.4. Metabolic & Genetic Diseases
    • 5.4.1. Metabolic & Genetic Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 5.5. Cardiovascular & Cerebrovascular Diseases
    • 5.5.1. Cardiovascular & Cerebrovascular Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)

Chapter 6. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market End Use Estimates & Trend Analysis

  • 6.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By End Use Key Takeaways
  • 6.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market End Use Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Biotech Companies
    • 6.3.1. Innovative Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 6.4. Pharmaceutical companies
    • 6.4.1. Pharmaceutical companies Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 6.5. Government & Academic Research Institutes
    • 6.5.1. Government & Academic Research Institutes Market Estimates And Forecasts, 2020 - 2030 (USD Million)

Chapter 7. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Regional Analysis

  • 7.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Regional market share analysis, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Market estimates and forecast, 2020 - 2030
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Market estimates and forecast, 2020 - 2030
    • 7.2.3. Canada
      • 7.2.3.1. Canada Market estimates and forecast, 2020 - 2030
  • 7.3. Europe
    • 7.3.1. Europe Market estimates and forecast, 2020 - 2030
    • 7.3.2. UK
      • 7.3.2.1. UK Market estimates and forecast, 2020 - 2030
    • 7.3.3. Germany
      • 7.3.3.1. Germany Market estimates and forecast, 2020 - 2030
    • 7.3.4. France
      • 7.3.4.1. France Market estimates and forecast, 2020 - 2030
    • 7.3.5. Italy
      • 7.3.5.1. Italy Market estimates and forecast, 2020 - 2030
    • 7.3.6. Spain
      • 7.3.6.1. Spain Market estimates and forecast, 2020 - 2030
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Market estimates and forecast, 2020 - 2030
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Market estimates and forecast, 2020 - 2030
    • 7.3.9. Norway
      • 7.3.9.1. Norway Market estimates and forecast, 2020 - 2030
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Market estimates and forecast, 2020 - 2030
    • 7.4.2. Japan
      • 7.4.2.1. Japan Market estimates and forecast, 2020 - 2030
    • 7.4.3. China
      • 7.4.3.1. China Market estimates and forecast, 2020 - 2030
    • 7.4.4. India
      • 7.4.4.1. India Market estimates and forecast, 2020 - 2030
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Market estimates and forecast, 2020 - 2030
    • 7.4.6. Australia
      • 7.4.6.1. Australia Market estimates and forecast, 2020 - 2030
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Market estimates and forecast, 2020 - 2030
    • 7.4.8. South Korea
      • 7.4.8.1. South Korea Market estimates and forecast, 2020 - 2030
  • 7.5. Latin America
    • 7.5.1. Latin America Market estimates and forecast, 2020 - 2030
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Market estimates and forecast, 2020 - 2030
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Market estimates and forecast, 2020 - 2030
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Market estimates and forecast, 2020 - 2030
    • 7.5.5. Colombia
      • 7.5.5.1. Colombia Market estimates and forecast, 2020 - 2030
    • 7.5.6. Chile
      • 7.5.6.1. Chile Market estimates and forecast, 2020 - 2030
  • 7.6. MEA
    • 7.6.1. MEA Market estimates and forecast, 2020 - 2030
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Market estimates and forecast, 2020 - 2030
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Market estimates and forecast, 2020 - 2030
    • 7.6.4. UAE
      • 7.6.4.1. UAE Market estimates and forecast, 2020 - 2030
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Market estimates and forecast, 2020 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Danaher (Aldevron)
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Recipharm AB
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Biomay AG
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Samsung Biologics
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Lonza
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Catalent , Inc.
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Bio-Indication Inc,
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. eTheRNA
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Kaneka Eurogentec S.A
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. TriLink BioTechnologies
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. ApexBio Technology
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. BioNTech SE.
      • 8.3.12.1. Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Service Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. Biocina
      • 8.3.13.1. Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Service Benchmarking
      • 8.3.13.4. Strategic Initiatives
Show more
Product Code: GVR-4-68040-083-7

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 4 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 5 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 6 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by region, 2020 - 2030 (USD Million)
  • Table 7 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 8 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 9 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 10 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 11 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 12 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 13 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 14 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020-2030, (USD million
  • Table 15 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 16 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 17 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 18 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 19 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 20 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 21 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 22 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 23 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 24 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 25 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 26 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 27 France mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 28 France mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 29 France mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 30 France mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 31 Italy mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 32 Italy mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 33 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 34 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 35 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 36 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 37 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 38 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 39 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 40 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 41 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 42 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 43 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 44 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 45 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 46 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 47 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 48 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 49 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 50 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 51 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 52 China mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 53 China mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 54 China mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 55 India mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 56 India mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 57 India mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 58 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 59 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 60 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 61 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 62 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 63 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 64 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 65 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 66 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 67 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 68 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 69 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 70 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 71 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 72 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 73 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 74 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 75 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 76 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 77 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 78 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 79 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 80 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 81 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 82 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 83 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 84 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 85 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 86 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 87 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 88 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 89 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 90 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 91 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 92 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 93 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 94 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 95 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 96 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)

List of Figures

  • Fig. 1 mRNA therapeutics contract development and manufacturing (CDMO) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 Related/ancillary market outlook
  • Fig. 14 mRNA Therapeutics Contract Development and Manufacturing (CDMO) - Industry value chain analysis
  • Fig. 15 mRNA therapeutics contract development and manufacturing (CDMO) market driver analysis
  • Fig. 16 mRNA therapeutics contract development and manufacturing (CDMO) market restraint analysis
  • Fig. 17 mRNA therapeutics contract development and manufacturing (CDMO) market: Porter's analysis
  • Fig. 18 mRNA therapeutics contract development and manufacturing (CDMO) market: PESTLE analysis
  • Fig. 19 mRNA therapeutics contract development and manufacturing (CDMO) market: application outlook and key takeaways
  • Fig. 20 mRNA therapeutics contract development and manufacturing (CDMO) market: application market share analysis, 2022 - 2030
  • Fig. 21 Global viral vaccines development market, 2020 - 2030 (USD Million)
  • Fig. 22 Global protein replacement therapies market, 2020 - 2030 (USD Million)
  • Fig. 23 Global cancer immunotherapies market, 2020 - 2030 (USD Million)
  • Fig. 24 mRNA therapeutics contract development and manufacturing (CDMO) market: Indication outlook and key takeaways
  • Fig. 25 mRNA therapeutics contract development and manufacturing (CDMO) market: Indication market share analysis, 2022 - 2030
  • Fig. 26 Global infectious diseases market, 2020 - 2030 (USD Million)
  • Fig. 27 Global metabolic & genetic diseases market, 2020 - 2030 (USD Million)
  • Fig. 28 Global cardiovascular and cerebrovascular diseases market, 2020 - 2030 (USD Million)
  • Fig. 29 mRNA therapeutics contract development and manufacturing (CDMO) market: End-user outlook and key takeaways
  • Fig. 30 mRNA therapeutics contract development and manufacturing (CDMO) market: End-user market share analysis, 2022 - 2030
  • Fig. 31 Global biotech companies market, 2020 - 2030 (USD Million)
  • Fig. 32 Global pharmaceutical companies market, 2020 - 2030 (USD Million)
  • Fig. 33 Global government & academic research institutes market, 2020 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 37 U.S. key country dynamics
  • Fig. 38 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 39 Canada key country dynamics
  • Fig. 40 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, 2020 - 2030 (USD Million)
  • Fig. 41 Europe mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 42 Germany key country dynamics
  • Fig. 43 Germany mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 44 UK key country dynamics
  • Fig. 45 UK mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 46 France key country dynamics
  • Fig. 47 France mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 48 Italy key country dynamics
  • Fig. 49 Italy mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 50 Spain key country dynamics
  • Fig. 51 Spain mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 52 Denmark key country dynamics
  • Fig. 53 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 54 Sweden key country dynamics
  • Fig. 55 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 56 Norway key country dynamics
  • Fig. 57 Norway mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 58 Asia-Pacific mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 59 Japan key country dynamics
  • Fig. 60 Japan mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 61 China key country dynamics
  • Fig. 62 China mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 63 India key country dynamics
  • Fig. 64 India mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 65 Australia key country dynamics
  • Fig. 66 Australia mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 67 Thailand key country dynamics
  • Fig. 68 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 69 South Korea key country dynamics
  • Fig. 70 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 71 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 72 Brazil key country dynamics
  • Fig. 73 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 74 Mexico key country dynamics
  • Fig. 75 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 76 Argentina key country dynamics
  • Fig. 77 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 78 MEA mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 79 South Africa key country dynamics
  • Fig. 80 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia key country dynamics
  • Fig. 82 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 83 UAE key country dynamics
  • Fig. 84 UAE mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 85 Kuwait key country dynamics
  • Fig. 86 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 87 Key company categorization
  • Fig. 88 Company market positioning
  • Fig. 89 Market participant categorization
  • Fig. 90 Strategy framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!